EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure

Dávid Tóthfalusi iD, Gréta Melani Csatlós, Boglárka Dobó, Fanni Borics iD, László Imre Pinczés iD, Árpád Illés, Zsófia Miltényi iD

Medicina · 12.04.2026 · 62 (4) · 738

DOI: 10.3390/medicina62040738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 12.04.2026. Verfasst von Dávid Tóthfalusi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary. Hauptthemen laut MEDLINE: Hodgkin Disease, Transplantation, Autologous, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Autologous stem cell transplantation (ASCT) remains the standard of care for relapsed or refractory Hodgkin lymphoma (R/R HL), and an increasing proportion of patients receive programmed cell death protein 1 (PD-1) inhibitors prior to transplantation. Engraftment syndrome (ES) is a noninfectious inflammatory complication classically associated with neutrophil recovery; however, early peri-transplant inflammatory manifestations remain poorly characterized and may mimic infectious complications. We aimed to evaluate peri-transplant inflammatory events after ASCT, with particular emphasis on ES-compatible manifestations occurring before neutrophil engraftment and their association with prior PD-1 inhibitor exposure. Materials and Methods: In this single-center retrospective cohort study, 64 consecutive adult patients with HL undergoing ASCT between 2018 and 2025 were analyzed. ES was defined according to Spitzer and Maiolino criteria. Inflammatory manifestations fulfilling these criteria but occurring prior to neutrophil recovery were classified as pre-engraftment syndrome (pre-ES). Clinically significant events were defined by the requirement for systemic corticosteroid therapy. Clinical and laboratory parameters were compared using non-parametric statistical analyses.

Results

No cases fulfilled the Spitzer criteria for classical ES, while three patients (4.7%) met the Maiolino criteria, none requiring corticosteroid therapy. Using the broader Maiolino definition, pre-ES was observed in 34 patients (53.1%) when the conventional engraftment time window was disregarded; however, only three patients required systemic corticosteroid therapy. Importantly, all three cases also fulfilled the Spitzer criteria outside the conventional time window, whereas the remaining Maiolino-defined pre-ES cases were self-limiting. All steroid-requiring pre-ES cases occurred exclusively in PD-1-exposed patients, and prior PD-1 therapy was significantly associated with severe pre-ES (p = 0.0007), although this finding is based on a very small number of events. These patients also demonstrated significantly higher early C-reactive protein (CRP) levels.

Conclusions

While classical ES after ASCT was uncommon, clinically significant pre-ES occurred exclusively in PD-1-exposed patients. These early inflammatory events may represent a distinct phenotype and require prompt recognition and timely corticosteroid therapy after exclusion of infection. Prospective studies are warranted to validate these findings and refine risk stratification and monitoring strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseTransplantation, AutologousImmune Checkpoint InhibitorsHematopoietic Stem Cell TransplantationHumansRetrospective StudiesFemaleAdultMaleMiddle AgedProgrammed Cell Death 1 ReceptorCohort Studies

Stichwörter der Autor:innen

Hodgkin lymphomaPD-1 inhibitorsautologous stem cell transplantationengraftment syndromeimmune checkpoint inhibitorsinflammatory complicationsperi-transplant manifestationspre-engraftment syndrome

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  • Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary.

ORCID-Profile: Dávid Tóthfalusi, Fanni Borics, László Imre Pinczés, Zsófia Miltényi

Zitieren

APA

Tóthfalusi, D., Csatlós, G. M., Dobó, B., Borics, F., Pinczés, L. I., Illés, Á., & Miltényi, Z. (2026). Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure. Medicina, 62(4), 738. https://doi.org/10.3390/medicina62040738

Vancouver

Tóthfalusi D, Csatlós GM, Dobó B, Borics F, Pinczés LI, Illés Á, et al. Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure. Medicina. 2026;62(4):738. doi:10.3390/medicina62040738

BibTeX
@article{Tthfalusi2026,
  author = {Tóthfalusi, Dávid and Csatlós, Gréta Melani and Dobó, Boglárka and Borics, Fanni and Pinczés, László Imre and Illés, Árpád and Miltényi, Zsófia},
  title = {Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {4},
  pages = {738},
  doi = {10.3390/medicina62040738}
}
Kostenlos starten →